Eli Lilly Required to Conduct Post-Marketing Studies for Obesity Drug Foundayo
Eli Lilly (LLY) has been mandated by the FDA to conduct post-marketing studies for its newly approved obesity drug, Foundayo. The requirement comes as part of the regulatory approval process for the drug, which is designed to monitor its long-term safety and efficacy. This development may impact investor confidence and the company's future obligations.
Tickers: $LLY
Topics: Eli Lilly FDA Foundayo post-marketing requirements weight loss pill